Tuesday, November 18, 2014

From 2014 ISHRS Meeting -Is a glaucoma drug the next treatment for hair loss?

ISHRS 2014 Meeting

Is a glaucoma drug the next treatment for hair loss?
Professor Valerie A. Randall, PhD, FIBMS, FSB
Professor of Biomedical Sciences, Centre for Skin Sciences, School of Life Sciences University of Bradford, Great Britain, U.K

Hair Loss causes significant negative effects on the quality of life of affected individuals. This occurs in every culture due to hair’s importance in human social and sexual communication across the world. As common as alopecia is, treatments are very limited and vary in their effectiveness. Current treatments involve cosmetic wigs or hairpieces to surgical techniques. The main medical therapies in current use include hormone action modifiers for androgen-dependent hair loss and non-hormonal treatments for other alopecias.

Glaucoma drugs are recently being researched for hair growth. They are used to reduce intraocular pressure, but seemed to stimulate eyelash growth as a side effect. Then came about Latisse (bimatoprost), previously a glaucoma drug that is now indicated for eyelash growth. Eyelash follicles differ from scalp hair as they specialize in the protection of the eyes. When bimatoprost was tested on isolated scalp follicles it showed increased human hair synthesis of organ cultures. It also stimulated hair growth in rodent pelage follicles. Bimatoprost appears to offer a new approach to stimulate scalp hair growth clinically. It is currently in phase 2 clinical trial in the US as a topically-applied treatment for androgenetic alopecia in men. Overall, increased understanding of the hair follicle function both in health and disease and careful observation of drug side-effects are leading to new approaches for therapies for alopecia.

From 2014 ISHRS Meeting -Aging Scalp and Gray Hair

Aging Scalp and Gray Hair

ISHRS 2014
Desmond J. Tobin, PhD, FSB, FRCPath.
Desmond J. Tobin is Professor of Cell Biology and Director of Centre for Skin Sciences at University of Bradford.

Although humans have over 5 million individual hair follicles on their bodies, most attention be it academic or commercial is focused on the paltry 2% of these that are distributed on our scalps. 

The hair follicle produces several different types of hair fiber during a normal lifetime. It is worth emphasizing that hair will grow up to 4 meters all  within the same single hair follicle. Hair growth rates also vary significantly during human aging and for different body sites. Indeed, when these are averaged for post-40 year old non-balding males, hair actually grows most rapidly and with greater individual fiber thickness in certain body sites in individuals during their 50-70 years of age. 

Increasing age can leave its mark on several phenotypic properties of the hair fiber. While the most visually apparent of these include hair thinning, hair loss, reduction in the rate of growth, pigmentation loss, aging can also affect change in the surface morphology of hair. The hair follicle is somewhat unusual however, in that some of its interactive cell systems appear to be non-essential for overall hair follicle survival. Indeed, strikingly gray and white hair follicles may paradoxically grow hair even more vigorously than their pigmented predecessors. 

Much of the recent research has focused on both the oxidative stress that appears to increase with aging and to which the hair follicle melanocytes appears especially sensitive, and the fate of hair follicle melanocyte stem cell capacity. This is likely to reflect significant differences in the epidermal and follicular melanocyte microenvironments.  The hair follicle may provide richer information in this context. Pre-proliferative, proliferative, differentiated, terminally-differentiated and ‘senescent‘ melanocytes all co-exist in the same growing hair follicle.